Lexeo Therapeutics, Inc. 8-K

What Happened

• Lexeo Therapeutics, Inc. held a virtual Annual Meeting of Stockholders on June 25, 2026 and filed an 8-K dated June 29, 2026 reporting the results. Stockholders elected three Class III directors to serve until the 2029 Annual Meeting and ratified KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
• Directors elected: R. Nolan Townsend, Brenda Cooperstone, M.D., and Paula HJ Cholmondeley. The auditor ratification vote approved KPMG LLP to continue as the company’s auditor for 2026.

Key Details

• Director election vote totals:
  • R. Nolan Townsend — For: 64,731,479; Withheld: 895,808; Broker non-vote: 9,955,777.
  • Brenda Cooperstone, M.D. — For: 48,792,570; Withheld: 16,834,717; Broker non-vote: 9,955,777.
  • Paula HJ Cholmondeley — For: 64,652,712; Withheld: 974,575; Broker non-vote: 9,955,777.
• Auditor ratification vote: For: 75,497,386; Against: 55,579; Abstain: 30,099.
• Elected directors will serve until the 2029 Annual Meeting or until their successors are qualified. Proxy materials were previously filed on April 30, 2026.

Why It Matters

• Board composition and leadership are set through 2029 for the Class III seats, which affects oversight of strategy and governance. The vote totals show differing shareholder support levels among nominees and a significant broker non-vote on director elections.
• Ratifying KPMG LLP provides continuity in external audit services for fiscal 2026, which is relevant for investors tracking the company’s financial reporting and audit oversight.
• These outcomes are routine corporate governance matters disclosed for investor transparency; see the company’s proxy filings for additional context.